Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 83-96, March 2006

Clinical use of plasma and plasma fractions

  • Richard K. Spence, MD, FACS (Chairman)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 410 368 2712; Fax: +1 410 951 4007.

Department of Surgery, St Agnes HealthCare, 900 Caton Ave., Mail Box 207, Baltimore, MD 21229, USA

The use of plasma and plasma-derived products has always involved a careful balance of anticipated benefit versus risk. Risk reduction through pathogen-inactivated products has been successful, but the expense of manufacture does not warrant widespread use. Although plasma has always had limited indications for use, these are often misunderstood or ignored in favor of received knowledge and tradition. Solid evidence from multiple trials support the limited indications for FFP described here and support products that target specific coagulation defects.

Key words: coagulopathy, cryoprecipitate, cryosupernatant, disseminated intravascular coagulation (DIC), fresh frozen plasma (FFP), surgical hemostasis, thrombotic–thrombocytopenic purpura (TTP), transfusion

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(05)00049-6

doi:10.1016/j.beha.2005.01.035

Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 83-96, March 2006

Article Tools